Your browser doesn't support javascript.
loading
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Horiike, Atsushi; Yamamoto, Nobuyuki; Tanaka, Hisashi; Yanagitani, Noriko; Kudo, Keita; Ohyanagi, Fumiyoshi; Ono, Akira; Naito, Tateaki; Murakami, Haruyasu; Horai, Takeshi; Nishio, Makoto.
Affiliation
  • Horiike A; Department of Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan. mnishio@jfcr.or.jp.
Anticancer Res ; 34(4): 1975-81, 2014 Apr.
Article in En | MEDLINE | ID: mdl-24692734
Subject(s)
Key words
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Carcinoma, Non-Small-Cell Lung / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Lung Neoplasms / Antineoplastic Agents Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Anticancer Res Year: 2014 Document type: Article Affiliation country: Japón Country of publication: Grecia
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Quinazolines / Carcinoma, Non-Small-Cell Lung / Drug Resistance, Neoplasm / Protein Kinase Inhibitors / Lung Neoplasms / Antineoplastic Agents Type of study: Etiology_studies / Risk_factors_studies Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Anticancer Res Year: 2014 Document type: Article Affiliation country: Japón Country of publication: Grecia